JPH203 (Nanvuranlat): A Novel LAT1 Inhibitor for Biliary Tract Cancer and Beyond
Exploring the groundbreaking structural insights into LAT1 and the therapeutic potential of JPH203 for cancer and other diseases.
Get a Quote & SampleProduct Core Value
LAT1 Inhibitor JPH203
JPH203, also known as Nanvuranlat, is a first-in-class, highly selective inhibitor of the L-type amino acid transporter 1 (LAT1). This transporter plays a crucial role in cellular nutrient uptake and is often overexpressed in various cancer cells, making it a key target for anti-cancer drug development. The detailed cryo-EM structures elucidate the precise binding modes of JPH203 to LAT1, revealing how it traps the transporter in an outward-facing state, effectively blocking substrate access and thus inhibiting cancer cell proliferation.
- Investigating the JPH203 mechanism of action provides deep insights into how LAT1 transporters are inhibited at a molecular level.
- The Nanvuranlat LAT1 inhibitor demonstrates remarkable selectivity, crucial for minimizing off-target effects in therapeutic applications.
- Understanding the LAT1 transporter structure is key to designing next-generation drugs that target this vital cellular pathway.
- Advancements in JPH203 clinical trials offer new hope for more effective biliary tract cancer treatment options.
Key Advantages
Targeted Inhibition
The precise inhibition mechanism of the LAT1 transporter by JPH203 offers a highly targeted approach to combatting diseases like cancer, aligning with strategies for advanced cancer treatment modalities.
Therapeutic Expansion
Beyond oncology, the development of JPH034 for multiple sclerosis highlights the broader therapeutic potential of targeting amino acid transport pathways, contributing to innovations in pharmaceutical research.
Structural Precision
The detailed structural insights into LAT1 substrate recognition and inhibition provide a robust foundation for future drug design, advancing the field of biochemical mechanisms of drug action.
Key Applications
Oncology
JPH203 is being actively developed for various cancers, with promising results in biliary tract cancer, showcasing its potential in LAT1 targeted cancer therapies.
Neurological Disorders
The related compound JPH034 is under investigation for multiple sclerosis, suggesting potential applications in treating neurological conditions through molecular targeting.
Drug Discovery Research
The structural and mechanistic data on LAT1 inhibition are invaluable for the broader field of drug discovery and development, aiding in the creation of novel therapeutic agents.
Biochemical Studies
The research provides critical data for understanding amino acid transport and the structure-activity relationships of LAT1 inhibitors, advancing biochemical studies.